Last reviewed · How we verify
TNF Inhibitor (W0-W12)
TNF inhibitors block tumor necrosis factor (TNF), a key inflammatory cytokine, to reduce inflammation and immune-mediated tissue damage.
TNF inhibitors block tumor necrosis factor (TNF), a key inflammatory cytokine, to reduce inflammation and immune-mediated tissue damage. Used for Rheumatoid arthritis, Inflammatory bowel disease (Crohn's disease, ulcerative colitis), Ankylosing spondylitis.
At a glance
| Generic name | TNF Inhibitor (W0-W12) |
|---|---|
| Sponsor | University Hospital, Montpellier |
| Drug class | TNF inhibitor |
| Target | TNF (tumor necrosis factor) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
TNF is a pro-inflammatory cytokine central to inflammatory and autoimmune diseases. TNF inhibitors work by binding to and neutralizing TNF or blocking its receptors (TNFR1/TNFR2), thereby suppressing the inflammatory cascade. This reduces immune cell activation, cytokine production, and tissue inflammation in conditions driven by TNF overexpression.
Approved indications
- Rheumatoid arthritis
- Inflammatory bowel disease (Crohn's disease, ulcerative colitis)
- Ankylosing spondylitis
- Psoriasis and psoriatic arthritis
Common side effects
- Increased infection risk (including tuberculosis, opportunistic infections)
- Injection site reactions
- Upper respiratory tract infections
- Headache
- Malignancy risk (lymphoma, solid tumors)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |